In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Mediocre results from the Phase 3a trial for cagrilintide and semaglutide #CagriSema in obesity and type 2 diabetes. Average weight loss at week 68 was 13.7% in the CagriSema group and 3.4% Cagrilintide Weight Loss Results: What Patients in Louisiana Need to Know Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News